The latest announcement is out from Cassava Sciences ( (SAVA) ).
Cassava Sciences announced the retirement of its Chief Medical Officer, James W. Kupiec, effective May 9, 2025, and the appointment of Jack Moore as Senior Vice President, Clinical Development. Moore will advance the clinical evaluation of simufilam in new potential indications, including TSC, leveraging his extensive experience in CNS disorders. The company also amended executive employment agreements, appointing R. Christopher Cook as Chief Operating and Legal Officer, reflecting strategic shifts in leadership to bolster its clinical development efforts.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges, including no revenue and operational losses, which weigh heavily on the stock’s potential. The technical analysis shows weak momentum, adding to concerns. However, the recent strategic partnership with Yale University provides a positive outlook for future growth, slightly improving the overall score.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing novel, investigational treatments for central nervous system disorders, including simufilam for tuberous sclerosis complex (TSC)-related epilepsy.
YTD Price Performance: -47.64%
Average Trading Volume: 1,690,364
Technical Sentiment Signal: Buy
Current Market Cap: $69.56M
See more data about SAVA stock on TipRanks’ Stock Analysis page.